Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
26.87
-0.39 (-1.43%)
Oct 12, 2026, 10:45 AM EDT - Market open
Zenas BioPharma Revenue
Zenas BioPharma had revenue of $1.00M in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $1.00M, down -93.33% year-over-year. In the year 2025, Zenas BioPharma had annual revenue of $10.00M with 100.00% growth. That makes Zenas BioPharma the 43,601st largest company in the world by revenue and 6,100th in the United States.
Revenue (ttm)
$1.00M
Revenue Growth
-93.33%
P/S Ratio
1,776.72
Revenue / Employee
$5,988
Employees
167
Market Cap
1.75B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.00M | 5.00M | 100.00% |
| Dec 31, 2024 | 5.00M | -45.00M | -90.00% |
| Dec 31, 2023 | 50.00M | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
ZBIO News
- 3 hours ago - Zenas BioPharma presents new obexelimab data - TheFly
- 5 days ago - Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026 - GlobeNewsWire
- 6 days ago - Zenas BioPharma to Host Virtual R&D Event - GlobeNewsWire
- 12 days ago - Zenas BioPharma price target raised to $48 from $41 at Citi - TheFly
- 13 days ago - Zenas BioPharma Transcript: Study update - Transcripts
- 13 days ago - Zenas BioPharma Slides: Study update - Filings
- 20 days ago - Zenas BioPharma announces new data from Phase 3 INDIGO trial on obexelimab - TheFly
- 20 days ago - Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026 - GlobeNewsWire